Dr Amaka O.
About Dr Amaka O.
Dr. Amaka O. is the Director and Global Regulatory Sciences Head for the UK/Ireland at Bristol Myers Squibb, with extensive experience in regulatory affairs and a strong commitment to improving patient access to medications.
Company
Dr. Amaka O. is currently with Bristol Myers Squibb as Director, Global Regulatory Sciences Head, UK/Ireland. The company is located in London, England, United Kingdom. She is responsible for overseeing regulatory strategies and their implementation within the UK and Ireland.
Title
Dr. Amaka O. holds the title of Director, Global Regulatory Sciences Head, UK/Ireland. In this role, she leads the regulatory sciences division and ensures compliance with pharmaceutical regulations while maximizing opportunities for earlier drug approvals and patient access.
Education and Expertise
Dr. Amaka O. has an extensive educational background. She studied at the University of Wales, Cardiff, where she completed modular courses in Pharmaceutical Regulatory Affairs from 2009 to 2012. She holds a Master's Degree in Toxicology from the University of Surrey, obtained in 2006. Additionally, she earned a Doctor of Veterinary Medicine (DVM) from the University of Nigeria, Nsukka, after seven years of study from 1995 to 2002. She also holds a PhD.
Career Background
Dr. Amaka O. has a diverse career background in regulatory affairs and clinical trials. She previously worked at Celgene as Senior Manager of Regulatory Affairs, Shire as Manager of Regulatory Affairs, and Bayer in various regulatory and project management roles. Her early career included clinical trials work at PPD and regulatory conformance at Pfizer.
Key Initiatives and Contributions
Dr. Amaka O. has led and contributed to several key initiatives. She guided the implementation of ILAP, Project Orbis, IRP, and Access Consortium, enhancing regulatory collaborations. Dr. Amaka directed regulatory assessments for integration activities and advised on strategic considerations for legal entity rationalization. She reviewed policy initiatives, supervised regulatory intelligence, and established a graduate program to support the GRS talent pipeline. Additionally, she worked on Windsor Framework impact mitigation strategies and facilitated leadership team portfolio strategy discussions.
Commitment to Health Equity and Patient Safety
Dr. Amaka O. is deeply committed to improving patient access to medications and advocating for health equity and care access for underserved patients. She ensures patient safety through Risk Evaluation and Mitigation Strategies (REMS) and has been involved in the development and implementation of REMS programs.